Clear Harbor Asset Management LLC Has $5.98 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Clear Harbor Asset Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 26.3% during the 3rd quarter, Holdings Channel.com reports. The fund owned 10,637 shares of the biopharmaceutical company’s stock after purchasing an additional 2,218 shares during the period. Clear Harbor Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $5,981,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in REGN. Brighton Jones LLC lifted its stake in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth about $226,000. Signature Estate & Investment Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 14.4% during the 1st quarter. Signature Estate & Investment Advisors LLC now owns 374 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 47 shares in the last quarter. Caxton Associates LLP acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $531,000. Finally, MBB Public Markets I LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $302,000. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on REGN shares. UBS Group upped their target price on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Hsbc Global Res upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. Finally, Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a research note on Friday, December 12th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $791.05.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $801.01 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. The firm’s 50-day moving average is $735.23 and its 200-day moving average is $626.08. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $816.99. The company has a market cap of $84.19 billion, a price-to-earnings ratio of 19.18, a PEG ratio of 2.42 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the business earned $12.46 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Insider Activity at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 8,431 shares of company stock worth $5,733,521. 7.02% of the stock is owned by corporate insiders.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America upgraded REGN from Underperform to Buy and lifted its price target to $860, citing improving fundamentals and 2026 catalysts, a clear bullish catalyst for the stock. Regeneron Pharmaceuticals upgraded by Bank of America
• Positive Sentiment: Truist raised its price target to $820 and reiterated a Buy, adding incremental upside and supporting analyst-driven demand. Truist raises price target
• Positive Sentiment: Aggregated analyst coverage is shifting more positive (multiple upgrade pieces and a roundup of 21 analyst views), which can drive buy-side interest and shorten-term momentum. 21 analysts assess Regeneron
• Neutral Sentiment: Unusual options activity has been reported, indicating increased speculative positioning and hedging that can amplify intraday moves but is ambiguous for longer-term direction. Unusual options activity
• Neutral Sentiment: Coverage pieces note falling short interest and renewed bullish cases; lower short interest reduces short-squeeze potential but supports steadier upside if fundamentals hold. Analyst upgrades and short-interest drop
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at ~$800 on Jan. 7, which can be viewed by some investors as a signal to take profits. Director share sale disclosed

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.